Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

Provided By GlobeNewswire

Last update: Mar 21, 2025

New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025